Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.
Journal article, 2013

Background: It is currently unknown whether early immunomodulatory treatment in relapsing–remitting MS (RRMS) can delay the transition to secondary progression (SP). Objective: To compare the time interval from onset to SP in patients with RRMS between a contemporary cohort, treated with first generation disease modifying drugs (DMDs), and a historical control cohort. Methods: We included a cohort of contemporary RRMS patients treated with DMDs, obtained from the Swedish National MS Registry (disease onset between 1995–2004, n = 730) and a historical population-based incidence cohort (onset 1950–64, n = 186). We retrospectively analyzed the difference in time to SP, termed the “period effect” within a 12-year survival analysis, using Kaplan-Meier and Cox regression analysis. Results: We found that the “period” affected the entire severity spectrum. After adjusting for onset features, which were weaker in the contemporary material, as well as the therapy initiation time, the DMD-treated patients still exhibited a longer time to SP than the controls (hazard ratios: men, 0.32; women, 0.53). Conclusion: Our results showed there was a longer time to SP in the contemporary subjects given DMD. Our analyses suggested that this effect was not solely driven by the inclusion of benign cases, and it was at least partly due to the long-term immunomodulating therapy given




multipel skleros




Helen Tedeholm

University of Gothenburg

Jan Lycke

University of Gothenburg

Bengt Skoog

University of Gothenburg

Vera Lisovskaja

University of Gothenburg

Chalmers, Mathematical Sciences, Mathematical Statistics

J Hillert

Karolinska University Hospital

C Dahle

Linköping University

J Fagius

Akademiska Sjukhuset

S Fredrikson

Karolinska University Hospital

A-M Landtblom

Linköping University

Clas Malmeström

University of Gothenburg

C Martin

Danderyd Hospital

F Piehl

Karolinska University Hospital

Björn Runmarker

University of Gothenburg

L Stawiarz

Karolinska University Hospital

M Vrethem

Linköping University

Olle Nerman

Chalmers, Mathematical Sciences, Mathematical Statistics

University of Gothenburg

Oluf Andersen

University of Gothenburg

Multiple Sclerosis

1352-4585 (ISSN) 1477-0970 (eISSN)

Vol. 19 6 765-774

Subject Categories

Clinical Medicine





More information

Latest update